Cigna Corp (CI): Today's Highlighted Laggard In Health Care

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Cigna ( CI) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.7%. By the end of trading, Cigna fell $1.53 (-2.3%) to $64.87 on average volume. Throughout the day, 2.7 million shares of Cigna exchanged hands as compared to its average daily volume of two million shares. The stock ranged in price between $64.52-$66.09 after having opened the day at $66.03 as compared to the previous trading day's close of $66.40. Other companies within the Health Care sector that declined today were: Urologix ( ULGX), down 11.1%, Tianyin Pharmaceutical ( TPI), down 9.5%, China Pharma ( CPHI), down 9.3%, and LCA-Vision ( LCAV), down 8.5%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. Cigna has a market cap of $18.64 billion and is part of the health services industry. The company has a P/E ratio of 11.6, below the S&P 500 P/E ratio of 17.7. Shares are up 24.2% year to date as of the close of trading on Tuesday. Currently there are nine analysts that rate Cigna a buy, no analysts rate it a sell, and five rate it a hold.

TheStreet Ratings rates Cigna as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows low profit margins.

On the positive front, Acura Pharmaceuticals ( ACUR), up 34%, Oragenics ( OGEN), up 25.4%, Oragenics ( ORNI), up 25.4%, and Alkermes ( ALKS), up 16.1%, were all gainers within the health care sector with Medivation ( MDVN) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.

null

More from Markets

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

GE Confirms $11.1 Billion Transportation Merger With Wabtec

GE Confirms $11.1 Billion Transportation Merger With Wabtec